From preclinical toxicology to clinical safety: The path for...
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
Newsletters and Deep Dive digital magazine
Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.
After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.
A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Editor's Picks
Newsletters and Deep Dive
digital magazine